Outgrowth of human liver metastases after resection of the primary colorectal tumor: A shift in the balance between apoptosis and proliferation

International Journal of Cancer

Volumn 119, Issue 6, 2006, Pages 1249-1253

  Peeters, Charlotte F J M ^a   De Waal, Robert M W ^a   Wobbes, Theo ^a   Westphal, Johan R ^a   Ruers, Theo J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Apoptosis; Colorectal cancer; Liver metastasis; Proliferation; Surgery

Indexed keywords

ANGIOSTATIN; CASPASE 3; ENDOSTATIN; KI 67 ANTIGEN;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESEARCH; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; COLON BIOPSY; COLORECTAL TUMOR; ENZYME ACTIVATION; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; MALE; MICROVASCULATURE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE 3; CASPASES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33747467117     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21928     Document Type: Article

References (28)

1. Sugarbaker E, Thorathwaite J, Ketcham A. Inhibitory effect of a primary tumor on metastasis. In Day SB, Myers WPL, Stansly P, Garattini S, Lewis MG, eds. Progress in cancer research and therapy. New York: Raven, 1977.227-40.
2. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1749-60.
3. Fischer B, Gunduz N, Saffer E. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43(4):1488-92.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987;123:1326-30.
6. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
7. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
8. Peeters CF, Westphal JR, De Waal RM, Ruiter DJ, Wobbes T. Ruers TJ. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer 2004;112:554-9.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
10. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
11. Thompson HJ, Strange R, Schedin PJ. Apoptosis in the genesis and prevention of cancer. Cancer Epidemiol Biomarkers Prev 1992; 1:597-602.
12. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor α. Cancer Res 1998;58:123-34.
13. Nakajima T, Kagawa K, Deguchi T, Kimura H, Kakusui M, Katagishi T, Mitsumoto Y, Okanoue T, Kashima K, Ashihara T. Novel formula for cell kinetics in xenograft model of hepatocellular carcinoma using histologically calculable parameters. Exp Cell Res 1999;246:412-20.
14. Li TS, Kaneda Y, Ueda K, Hamano K, Zempo N, Esato K. The influence of tumour resection on angiostatin levels and tumour growth-an experimental study in tumour-bearing mice. Eur J Cancer 2001;37:2283-8.
15. Sckell A, Safabakhsh N, Dellian M, Jain RK. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res 1998;28:5866-9.
16. Holmgren L, O'Reilly MS, Folkman S. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
17. Murray C. Tumour dormancy: not so sleepy after all. Nat Med 1995;1:117-8.
18. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
19. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
20. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR. Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
21. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-8.
22. Peeters CF, de Geus LF, Westphal JR, De Waal RM, Ruiter DJ, Wobbes T, Oyen WJ, Ruers TJ. Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 2005;137:246-9.
23. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 2000;60:1761-5.
24. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59:6251-6.
25. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
26. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
27. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-14.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.